Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials
Curr Issues Pharm Med Sci., Vol. 34, No. 3, 123-129
Syed Wasif Gillani1* 
, Anam Azhar2 , Shabaz Mohiuddin Gulam1 ,
Fithawit Bahran Gebreigziabher1 , Hassaan Anwer Rathore3
1 Department of Pharmacy Practice, College of Pharmacy Gulf Medical University, Ajman, United Arab Emirates
2 Pharm D candidates, College of Pharmacy Gulf Medical University, Ajman, United Arab Emirates
3 College of Pharmacy, Qatar University, Doha, Qatar
10.2478/cipms-2021-0024
© 2021 Author(s). This is an open access article distributed under the Creative Commons Attribution-NonComercial-No Derivs licence (http://creativecommons.org/licenses/by-nc-nd/3.0/)
Abstract
The objective of this meta-analysis study was to evaluate the comparative efficacy of empagliflozin (25 mg) with placebo in the treatment and management of type 1 diabetes mellitus. This study is a meta-analysis, so an ethical statement is not required. Different databases and individual journal websites like SCOPUS, Science direct, Cochrane review library etc. were used. The articles were evaluated based on the search and eligibility criteria. A total of five RCTs were incorporated in this meta-analysis. These studies contained a total of 1058 patients, including 526 patients with placebo (or control-treated patients), and 532 patients with empagliflozin (25 mg) treated combination. The mean follow-up time ranged from 7 days to 6 months. Overall, mean reduction in placebo was -0.50% and empa-treated was -0.85%, while the pooled WMD was 3.82 995% CI 1.20 – 5.88, p=0.0001). Regarding urinary glucose excretion, that the pooled WMD was 6.67 (95% CI 4.87-10.14, p=0.001) indicated a significant increase in empa-arm compared to placebo. No heterogeneity was found (I2 – 15.03%). This meta-analysis underlined the therapeutic benefit of empagliflozin as an adjunctive therapy for patients with type 1 diabetes.
Full Text
Keywords
meta-analysis, type 1 diabetes, empagliflozin, placebo, evidence-based practice.
References
- Zhou, Y, Geng, Z, Wang, X, Huang, Y, Shen, L, Wang, Y. Meta‐analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add‐on to metformin in type 2 diabetes. Diabetes Metab Res Rev. 2020;36:e3223.
- McNeill AM, Davies G, Kruger E, Kowal S, Reason T, Ejzykowicz F, et al. Ertugliflozin compared to other anti-hyperglycemic agents as monotherapy and add-on therapy in type 2 diabetes: A systematic literature review and network meta-analysis. Diabetes Ther. 2019;10(2):473‐91.
- Wang C, Zhou Y, Kong Z, Wang X, Lv W, Geng Z, et al. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(4):1018‐26.
- Deacon CF, Mannucci E, Ahrén B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes – a review and meta analysis. Diabetes Obes Metab. 2012;14(8):762‐7.
- Scheen AJ. Reduction in HbA1C with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1C: A systematic review of randomized controlled trials. Diabetes Metab. 2020;46(3):186‐96.
- Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014;16(1):30‐7.
- Liu XY, Zhang N, Chen R, Zhao JG, Yu P. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J Diabetes Complications. 2015;29(8):1295‐303.
- Castellana M, Cignarelli A, Brescia F, Perrini S, Natalicchio A, Laviola L, et al. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis. Sci Rep. 2019;9(1):19351. doi:10.1038/s41598-019-55524-w
- McHugh KR, De Vore AD, Mentz RJ, Edmonston D, Green JB, Hernandez AF. The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: a focus on cardiorenal outcomes. Clin Cardiol. 2018;41(9):1259-67.
- Wu S, Cipriani A, Yang Z, Yang J, Cai T, Xu Y, et al. The cardiovas-cular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis. Expert Opin Drug Saf. 2018;17(3):243-9.
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
- Rosenstock J, Marquard J, Laffel L, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to insulin therapy in Type 1 diabetes: The EASE Trials. Diabetes Care. 2018;41(12):2560-256.
- Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17:928-35.
- Shimada A, Hanafusa T, Yasui A, Lee G, Taneda Y, Sarashina S, et al. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial. Diabetes Obes Metab. 2018;20(9): 2190-9.
- Perkins B, Cherney D, Partridge H. et al. Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial. Diabetes Care. 2014;37(5):1480-3.
- Cherney D, Perkins B, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in participants with type 1 diabetes mellitus. Circ. 2014;129(5):587-97.
- Mathieu C, Eeckhout B. et al. Empagliflozin in type 1 diabetes. Diabetes Metab Syndr Obes. 2019;12:1555-61.
- Llano A, McKay G, Fisher M. SGLT inhibitors for people with type 1 diabetes. Practical Diabetes. 2019;36:3.
- Danne T, Garg S, Peters A, Buse JB, Mathieu C, Pettus JH, et al. International consensus on risk management of diabetic ketoacidosis in participants with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019;18:2316.
